Fish Oil Drug Looks Heart-Healthy. Just Don’t Swallow It Hook, Line And Sinker.

(By Shefali Luthra for Kaiser Health News)

When biopharma company Amarin teased its latest clinical trial results this fall, it stirred both buzz and controversy in the medical community by suggesting its drug, Vascepa, could transform heart disease prevention. The company’s stock skyrocketed. Continue reading article here…

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.